Salarius Pharmaceuticals successfully completed a reverse merger with Flex Pharma in August 2019, creating a quick liquidity event for VisionTech Angels investors. Salarius, which now trades on Nasdaq under SLRX, returned common stock to investors less than 10 months after their original investment. Salarius is an emerging biotechnology company developing targeted therapies to treat rare pediatric and other cancers, including advanced solid tumors. The company’s lead compound Seclidemstat represents a potential paradigm shift in the treatment of cancer with an initial target of Ewing sarcoma, a devastating pediatric, adolescent and young adult bone cancer where no targeted therapies are currently available.
Visit http://salariuspharma.com/